Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 08:00 ET
|
Yumanity Therapeutics Inc
BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics to Host Virtual R&D Day on Monday, May 17, 2021
May 04, 2021 08:00 ET
|
Yumanity Therapeutics Inc
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for neurodegenerative...
Yumanity Therapeutics to Present at the 2021 B. Riley Securities’ Neuroscience Conference
April 28, 2021 20:07 ET
|
Yumanity Therapeutics Inc
BOSTON, April 28, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics’ YTX-7739 Achieved Target Engagement at Doses That Were Generally Well Tolerated in a Phase 1a Multiple Ascending Dose Study in Healthy Volunteers
April 22, 2021 07:00 ET
|
Yumanity Therapeutics Inc
BOSTON, April 22, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Appoints Neuroscience Drug Development Veteran, Ajay Verma, M.D., Ph.D., Executive Vice President, Head of Research & Development
April 13, 2021 08:00 ET
|
Yumanity Therapeutics Inc
BOSTON, April 13, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a biopharmaceutical company focused on the development of innovative, disease-modifying therapies for...
Yumanity Therapeutics Announces Study Demonstrating In Vivo Efficacy of YTX-7739 in a Glioblastoma Multiforme (GBM) Mouse Model
April 06, 2021 08:00 ET
|
Yumanity Therapeutics Inc
YTX-7739 demonstrates efficacy, including increased median overall survival, both as a single agent and in combination with temozolomide, the standard-of-care for GBM Shared therapeutic target with...
Yumanity Therapeutics Reports Full Year 2020 Financial Results and Recent Corporate Developments
March 31, 2021 08:48 ET
|
Yumanity Therapeutics Inc
Closed $33.6 million PIPE in conjunction with the completion of reverse merger with Proteostasis Therapeutics; commenced trading on the Nasdaq Capital Market under the ticker symbol “YMTX” ...
Yumanity Therapeutics’ YTX-7739 Demonstrates Prevention of Motor Function Deficits in a Parkinson’s Disease Mouse Model
March 09, 2021 08:00 ET
|
Yumanity Therapeutics Inc
YTX-7739 demonstrates pharmacological, physiological, and behavioral pre-clinical proof of concept in in vivo model Study presented at AD/PD™ 2021 BOSTON, March 09, 2021 (GLOBE NEWSWIRE) --...
Yumanity Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
March 02, 2021 16:05 ET
|
Yumanity Therapeutics Inc
BOSTON, March 02, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
Yumanity Therapeutics Provides Update on Its Lead Parkinson’s Disease Clinical Program, YTX-7739
February 10, 2021 08:00 ET
|
Yumanity Therapeutics Inc
Results reported of the single ascending dose study in healthy volunteers Enrollment completed of the multiple ascending dose study in healthy volunteers; results expected by end of Q1 2021 ...